In a nutshell This study was carried out to assess the long-term safety and effectiveness of magnetic resonance imaging (MRI)-guided transurethral ultrasound ablation (TULSA) in patients with localized prostate cancer. The authors found that TULSA was safe and effective, with preserved quality of life. Some background Prostate cancer is one...
Read More
In a nutshell This study investigated the effectiveness of treatment with irinotecan (Camptosar) combined with capecitabine (Xeloda) chemotherapy (ICC) before rectal cancer surgery. Researchers suggested that this combined therapy significantly improved the treatment outcomes in these patients. Some background Rectal cancer is a common...
Read More
In a nutshell This study will investigate the safety and effectiveness of tiragolumab combined with atezolizumab (Tecentriq) and chemotherapy to treat triple-negative breast cancer (TNBC). The main outcome will be the occurrence of side effects and the objective response rate (ORR). The details Breast cancer (BC) is the most...
Read More
In a nutshell This study investigated the long-term changes in sexual function (SF) in men after rectal cancer surgery. Researchers suggested that SF was not significantly affected by rectal cancer surgery. Some background Colorectal cancer is the third most common cancer worldwide. Of these, around 30% are rectal cancers. Newer cancer therapies...
Read More
In a nutshell This study looked at the role of circulating tumor DNA (ctDNA) in predicting treatment response in advanced melanoma. They found that in patients treated for the first time with immune treatment, patients with low ctDNA levels had a longer survival without cancer worsening. Some background Advanced melanoma describes melanoma...
Read More
In a nutshell This study looked at the safety and effectiveness of atezolizumab (Tecentriq) compared to platinum-based chemotherapy for the treatment of advanced lung cancer. They found that atezolizumab improved survival compared to chemotherapy in these patients. Some background Lung cancer is classified based on how the tumor cells look...
Read More
In a nutshell This trial was carried out to assess the effectiveness and safety of osimertinib (Tagrisso) after surgery for EGFR-positive advanced non-small cell lung cancer (NSCLC). The trial found that this treatment improved the outcomes of patients with stage IB to IIIA EGFR-positive NSCLC that was surgically removed. Some...
Read More
In a nutshell The study compared outcomes of adjuvant radiotherapy (AR) versus observation with salvage radiotherapy (SR) in patients with prostate cancer (PCa) after radical prostatectomy (RP). The authors found that careful observation with SR is a safer treatment after RP for preventing cancer progression. Some background RP surgically removes the...
Read More
In a nutshell This study is looking to recruit patients with prostate cancer (PC) spread to the bone to trial internal and external radiotherapy. The main outcome that will be measured is the length of time until patients need androgen deprivation therapy (ADT). This trial will be carried out in Utah, the United States. The details PC...
Read More
In a nutshell This study investigated the short-term functional measures and complications for high-intensity focused ultrasound (HIFU) treatment in half of the prostate gland (hemi-gland) for patients with prostate cancer (PCa). The study showed that hemi-gland HIFU is a low-risk surgery and provides maintenance of sexual and urinary...
Read More
In a nutshell This trial was carried out to examine the use of recombinant human (rh) endostatin (EN) with CT before surgery in patients with breast cancer (BC). The authors concluded that the addition of EN to CT significantly improved the response rate to therapy and survival in these patients. Some background BC is the most common form of...
Read More
In a nutshell The study evaluated outcomes of brigatinib (Alunbrig) versus crizotinib (Xalkori) in patients with non-small cell lung carcinoma (NSCLC) and anaplastic lymphoma kinase (ALK) mutations, who were previously not treated with ALK inhibitors (ALKI). The main finding was that brigatinib had better long-term outcomes compared to crizotinib in such...
Read More
